Does low egg count mean low egg quality too?

Why are egg quantity and egg quality different biological parameters?

Egg quantity reflects the size of the remaining follicular pool: how many eggs are still available to be recruited into maturation cycles. This pool is determined by the original number of follicles a woman was born with, minus the follicles that have been lost to ovulation and atresia (natural cell death) over her lifetime. AMH measures this remaining pool indirectly through the hormone produced by small developing follicles.

Egg quality reflects what happens to an individual egg during its 90-day maturation process: whether chromosomes segregate accurately during meiosis, whether mitochondria produce sufficient ATP, and whether the cellular architecture of the egg is intact enough to support fertilization and early embryo development. These processes occur inside individual follicles and are determined by the physiological environment surrounding those follicles, not by how many follicles remain.

The distinction matters because the mechanisms that deplete the follicular pool and the mechanisms that impair individual egg quality are largely independent:

• Age depletes the follicular pool through continuous atresia and reduces chromosomal segregation accuracy through spindle deterioration. Both processes are driven by age, but through separate biological pathways.
• Mitochondrial function, oxidative stress, and follicular environment quality are shaped by physiological health choices during the maturation window, not by how many follicles remain in the pool.
• A woman can have a depleted pool of follicles from which the remaining eggs mature in an excellent mitochondrial and low-oxidative-stress environment.

Research published in Human Reproduction confirmed that AMH level was not a significant predictor of per-egg chromosomal normalcy rate in PGT-tested IVF cycles after controlling for patient age, directly supporting the independence of quantity and chromosomal quality.

What does the research actually show about AMH and egg quality?

The research on AMH and egg quality is more nuanced than the clinical shorthand of low AMH equals poor quality suggests. Studies consistently show that age, not AMH, is the dominant predictor of chromosomal egg quality. AMH predicts the number of eggs available, not the quality of each individual egg.

Key findings from the research:

• A large IVF outcomes study published in Fertility and Sterility found that euploid embryo rate per egg retrieved did not differ significantly between women with low AMH and women with normal AMH of the same age, confirming that AMH does not predict per-egg chromosomal normalcy independent of age.
• Women with low AMH do produce fewer total euploid embryos per retrieval than women with high AMH of the same age, but this is a mathematical consequence of retrieving fewer eggs, not a reduction in the per-egg probability of chromosomal normalcy.
• A study in the Journal of Assisted Reproduction and Genetics found that among women over 38 with DOR, per-egg blastocyst development rate and euploid rate were equivalent to those of age-matched high-responders. The DOR group produced fewer blastocysts per cycle only because they produced fewer eggs, not because each egg was less likely to become a euploid blastocyst.

These findings have a direct clinical implication: if you retrieve only 3 eggs in a DOR cycle and all 3 are mature and fertilize, the probability that at least one is chromosomally normal is determined by your age, not by your AMH. The AMH determined that you retrieved 3 eggs rather than 10. It did not reduce the quality of any of them.

Why does the quality-quantity confusion happen so often?

The conflation of egg quantity and egg quality is one of the most common and consequential misunderstandings in fertility medicine. It happens for several reasons that are worth understanding because they shape how the numbers get communicated.

Sources of the confusion:

• AMH and age are correlated in the population: older women tend to have lower AMH and lower egg quality simultaneously, simply because age drives both. When AMH and quality are analyzed at the population level without controlling for age, they appear correlated. The correlation disappears when age is held constant.
• Lower egg numbers mean fewer chances to find a euploid embryo: a woman who retrieves 10 eggs and a woman who retrieves 3 eggs of the same age have the same per-egg euploid probability, but the first woman will find more euploid embryos per cycle. This practical difference (fewer total euploid embryos) gets communicated as a quality difference when it is actually a quantity difference playing out in the math of the outcome.
• Clinical shorthand: in busy clinical settings, the statement that low AMH means poor egg quality is a simplification that saves time. It is not an accurate representation of the biology, but it is a common one.
• Emotional framing of the conversation: conversations about DOR often occur in the context of guiding a woman toward donor eggs. Framing low AMH as poor quality makes that recommendation feel more supported than framing it accurately as low quantity.

Research in Human Reproduction Update found that patient understanding of the AMH-quality distinction significantly affected willingness to pursue own-egg IVF versus donor egg treatment, with women who were accurately informed about the quantity-quality independence being more likely to attempt own-egg IVF before transitioning to donor eggs.

What actually predicts egg quality if AMH does not?

Egg quality in any given cycle is most accurately predicted by age (for the chromosomal component), by the physiological markers that reflect the follicular environment (for the mitochondrial and oxidative components), and by prior cycle embryology findings (for the complete picture of how eggs have actually performed).

The most informative predictors of egg quality:

• Age: the strongest predictor of per-egg chromosomal normalcy. Per-egg euploid rates decline predictably with age regardless of AMH level. This is the quality factor that cannot be changed.
• Prior cycle embryology data: fertilization rate, day-3 embryo quality scores, blastocyst conversion rate, and PGT results from prior cycles are the most direct available evidence of actual egg performance. These numbers describe what eggs from this woman, in this body, in this physiological state, actually produced. They are more informative than AMH for quality prediction.
• Systemic inflammatory markers: hs-CRP and homocysteine correlate with follicular fluid oxidative stress, which directly impairs egg quality at the mitochondrial and chromosomal level.
• Mitochondrial support status: CoQ10 levels are not routinely measured, but their absence from a supplement protocol in a woman with prior poor embryo development is a quality-relevant gap.
• Follicular fluid composition markers: available only at retrieval, but oxidative stress markers in follicular fluid have been shown to predict embryo quality in the same cycle more accurately than AMH measured beforehand.

A 2022 review in Reproductive Sciences found that a quality prediction model using age, prior cycle embryo development data, and systemic inflammatory markers outperformed AMH as a quality predictor in women with DOR who had undergone multiple IVF cycles.

What should I focus on if I have low AMH but want to improve egg quality?

If you have low AMH, the quality of each egg you do produce matters more, not less, because there are fewer eggs to work with. This makes the 90-day window before retrieval and the egg quality factors within your influence more important in DOR than in high-reserve women, not less.

The most high-leverage quality interventions for women with DOR:

• CoQ10 at 400 to 600 mg daily in ubiquinol form: mitochondrial energy capacity per egg is the most directly addressable quality factor. In women with fewer eggs, maximizing the mitochondrial function of each one produces a proportionally larger impact on outcomes.
• Vitamin D optimization to 50 to 80 ng/mL: supports both granulosa cell function around each developing follicle and chromosomal segregation accuracy in the final maturation phase.
• Anti-inflammatory dietary pattern: reducing follicular fluid oxidative stress through systemic inflammation reduction protects the cellular integrity of developing eggs in low-reserve women as effectively as in high-reserve women.
• Thyroid optimization: if thyroid antibodies or suboptimal TSH are present, addressing them removes a quality-suppressing factor from the follicular environment.
• Stress physiology management: HPA axis suppression of LH pulsatility impairs the final maturation signal for each developing follicle. In low-reserve women where each follicle counts, the quality of the ovulatory signal matters particularly.

Research published in the Journal of Ovarian Research found that women with DOR who completed a 90-day egg quality protocol showed improved fertilization rates and blastocyst development rates per egg retrieved compared to their own prior cycles, with no change in the number of eggs retrieved, confirming that quality improvement is achievable in low-reserve women independently of quantity.